Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -87.86% is 85% below its 5-year average of -47.55%, near the low end of its 5-year range (-87.86%–-7.39%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.81% below its 12-month average of -68.21%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -87.86%.
RETURN ON EQUITY (ROE)
-87.86%
RETURN ON EQUITY (ROE) AVG TTM
-68.21%
RETURN ON EQUITY (ROE) AVG 3Y
-50.86%
RETURN ON EQUITY (ROE) AVG 5Y
-47.55%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-28.81%
CURRENT VS 3Y AVG
-72.76%
CURRENT VS 5Y AVG
-84.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-109.15%
vs the sector median at left
Treace Medical Concepts, Inc.
Market Cap
$259.49M
Return on Equity (ROE)
-87.86%
TTM Avg
-68.21%
3Y Avg
-50.86%
5Y Avg
-47.55%
Market Cap
$259.56M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$259.14M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
Market Cap
$259.12M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
Market Cap
$258.63M
Return on Equity (ROE)
-26.24%
TTM Avg
-102.84%
3Y Avg
-107.17%
5Y Avg
-107.44%
Market Cap
$261.27M
Return on Equity (ROE)
-57.98%
TTM Avg
-105.80%
3Y Avg
-134.08%
5Y Avg
-126.56%
Market Cap
$261.43M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$256.47M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$262.92M
Return on Equity (ROE)
-430.72%
TTM Avg
122.09%
3Y Avg
211.60%
5Y Avg
136.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Treace Medical Concepts, Inc. (TMCI) | $259.49M | -87.86% | -68.21% | -50.86% | -47.55% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -15.46% | -12.46% | -4.29% | -4.49% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | -38.33% | -61.68% | -393.03% | -278.88% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | -37.12% | -62.34% | -32.67% | 8.91% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -26.24% | -102.84% | -107.17% | -107.44% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -57.98% | -105.80% | -134.08% | -126.56% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | -39.55% | -28.46% | -79.02% | -63.95% |
| AC Immune S.A. (ACIU)vs › | $256.47M | -124.67% | -101.06% | -69.44% | -56.33% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -430.72% | 122.09% | 211.60% | 136.09% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -2.76% | -22.10% | -22.09% | -15.95% |
ROE
-87.9%
ROA
-32.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -87.86% |
| 2026-03-31 | -79.08% |
| 2025-12-31 | -67.56% |
| 2025-09-30 | -56.18% |
| 2025-06-30 | -50.38% |
| 2025-03-31 | -50.30% |
| 2024-12-31 | -49.38% |
| 2024-09-30 | -58.65% |
| 2024-06-30 | -56.79% |
| 2024-03-31 | -43.32% |
| 2023-12-31 | -35.91% |
| 2023-09-30 | -34.57% |
| 2023-06-30 | -28.19% |
| 2023-03-31 | -29.97% |
| 2022-12-31 | -70.73% |
| 2022-09-30 | -72.38% |
| 2022-06-30 | -54.81% |
| 2022-03-31 | -31.28% |
| 2021-12-31 | -22.08% |
| 2021-09-30 | -11.67% |
| 2021-06-30 | -7.39% |
| 2020-12-31 | -472.68% |
